{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:40:11Z","timestamp":1792359611833,"version":"4.4.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,18]]},"DOI":"10.7759\/cureus.118129","type":"journal-article","created":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:00:57Z","timestamp":1792357257000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment Strategies for Achieving and Maintaining Low-Risk Status in Pulmonary Arterial Hypertension: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Shahbaz Younas","family":"Chaoddhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Ram Kumar","family":"Yatiraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Chellamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eazaz Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farooq","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Happiness","family":"Olaniyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmanpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliyu O","family":"Olaniyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert M","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al.. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022, 43:3618-731. 10.1093\/eurheartj\/ehac237","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8 N","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, et al.. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015, 373:834-44. 10.1056\/NEJMoa1413687","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"39","author":"Kylhammar D","year":"2018","unstructured":"Kylhammar D, Kjellstr\u00f6m B, Hjalmarsson C, et al.. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018, 39:4175-81. 10.1093\/eurheartj\/ehx257","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies","volume":"156","author":"Benza RL","year":"2019","unstructured":"Benza RL, Gomberg-Maitland M, Elliott CG, et al.. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies. Chest. 2019, 156:323-37. 10.1016\/j.chest.2019.02.004","journal-title":"Chest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza RL","year":"2021","unstructured":"Benza RL, Kanwar MK, Raina A, et al.. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest. 2021, 159:337-46. 10.1016\/j.chest.2020.08.2069","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02311-2021","article-title":"COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension","volume":"60","author":"Hoeper MM","year":"2022","unstructured":"Hoeper MM, Pausch C, Olsson KM, et al.. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022, 60:10.1183\/13993003.02311-2021","journal-title":"Eur Respir J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02419-2021","article-title":"External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry","volume":"59","author":"Boucly A","year":"2022","unstructured":"Boucly A, Weatherald J, Savale L, et al.. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur Respir J. 2022, 59:10.1183\/13993003.02419-2021","journal-title":"Eur Respir J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oead012","article-title":"Evaluation of the European Society of Cardiology\/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator","volume":"3","author":"Ahmed A","year":"2023","unstructured":"Ahmed A, Ahmed S, Kempe D, R\u00e5degran G. Evaluation of the European Society of Cardiology\/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator. Eur Heart J Open. 2023, 3:oead012. 10.1093\/ehjopen\/oead012","journal-title":"Eur Heart J Open"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper MM","year":"2023","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA, et al.. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023, 388:1478-90. 10.1056\/NEJMoa2213558","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415160","article-title":"Sotatercept in patients with pulmonary arterial hypertension at high risk for death","volume":"392","author":"Humbert M","year":"2025","unstructured":"Humbert M, McLaughlin VV, Badesch DB, et al.. Sotatercept in patients with pulmonary arterial hypertension at high risk for death. N Engl J Med. 2025, 392:1987-2000. 10.1056\/NEJMoa2415160","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034151","article-title":"Prognostic value of serial risk stratification in adult and pediatric pulmonary arterial hypertension: a systematic review","volume":"13","author":"Lokhorst C","year":"2024","unstructured":"Lokhorst C, van der Werf S, Berger RM, Douwes JM. Prognostic value of serial risk stratification in adult and pediatric pulmonary arterial hypertension: a systematic review. J Am Heart Assoc. 2024, 13:e034151. 10.1161\/JAHA.123.034151","journal-title":"J Am Heart Assoc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.08.2203","article-title":"Retrospective validation of the REVEAL 2.0 risk score with the Australian and New Zealand pulmonary hypertension registry cohort","volume":"157","author":"Anderson JJ","year":"2020","unstructured":"Anderson JJ, Lau EM, Lavender M, et al.. Retrospective validation of the REVEAL 2.0 risk score with the Australian and New Zealand pulmonary hypertension registry cohort. Chest. 2020, 157:162-72. 10.1016\/j.chest.2019.08.2203","journal-title":"Chest"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden JA","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013, 158:280-6. 10.7326\/0003-4819-158-4-201302190-00009","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell M","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A, et al.. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020, 368:l6890. 10.1136\/bmj.l6890","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15134924","article-title":"Sequential add-on therapy modifies mortality risk stratification in group 1.4 pulmonary arterial hypertension","volume":"15","author":"Cortes-Telles A","year":"2026","unstructured":"Cortes-Telles A, Priego-Escamilla YV, Ort\u00edz-Farias DL, V\u00e1zquez-L\u00f3pez S, Pou-Aguilar YN, Figueroa-Hurtado E. Sequential add-on therapy modifies mortality risk stratification in group 1.4 pulmonary arterial hypertension. J Clin Med. 2026, 15:4924. 10.3390\/jcm15134924","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/resp.14247","article-title":"Characteristics, goal-oriented treatments and survival of pulmonary arterial hypertension in China: insights from a national multicentre prospective registry","volume":"27","author":"Quan R","year":"2022","unstructured":"Quan R, Zhang G, Yu Z, et al.. Characteristics, goal-oriented treatments and survival of pulmonary arterial hypertension in China: insights from a national multicentre prospective registry. Respirology. 2022, 27:517-28. 10.1111\/resp.14247","journal-title":"Respirology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead360","article-title":"Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis","volume":"63","author":"Distler O","year":"2024","unstructured":"Distler O, Ofner C, Huscher D, et al.. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis. Rheumatology (Oxford). 2024, 63:1139-46. 10.1093\/rheumatology\/kead360","journal-title":"Rheumatology (Oxford)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.14744\/AnatolJCardiol.2023.2885","article-title":"Risk assessment tool implementation in congenital heart disease-associated pulmonary arterial hypertension","volume":"27","author":"Yaylal\u0131 YT","year":"2023","unstructured":"Yaylal\u0131 YT, Ya\u011fmur B, Sinan \u00dcY, et al.. Risk assessment tool implementation in congenital heart disease-associated pulmonary arterial hypertension. Anatol J Cardiol. 2023, 27:479-85. 10.14744\/AnatolJCardiol.2023.2885","journal-title":"Anatol J Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcrp.2024.200294","article-title":"Clinical outcomes of upfront combination therapy for portopulmonary hypertension","volume":"22","author":"Kiko T","year":"2024","unstructured":"Kiko T, Asano R, Endo H, et al.. Clinical outcomes of upfront combination therapy for portopulmonary hypertension. Int J Cardiol Cardiovasc Risk Prev. 2024, 22:200294. 10.1016\/j.ijcrp.2024.200294","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac604","article-title":"Long-term follow-up of human immunodeficiency virus-associated pulmonary hypertension: clinical features and survival outcomes of the Pan Africa Pulmonary Hypertension Cohort (PAPUCO)","volume":"9","author":"Thienemann F","year":"2022","unstructured":"Thienemann F, Katoto PD, Azibani F, et al.. Long-term follow-up of human immunodeficiency virus-associated pulmonary hypertension: clinical features and survival outcomes of the Pan Africa Pulmonary Hypertension Cohort (PAPUCO). Open Forum Infect Dis. 2022, 9:ofac604. 10.1093\/ofid\/ofac604","journal-title":"Open Forum Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.06.023","article-title":"Do patients with low-risk pulmonary arterial hypertension really benefit from upfront combination therapy? Insight from the AMBITION trial","volume":"164","author":"Fauvel C","year":"2023","unstructured":"Fauvel C, Liu Y, Correa-Jaque P, Kanwar MK, Vizza CD, Lin S, Benza RL. Do patients with low-risk pulmonary arterial hypertension really benefit from upfront combination therapy? Insight from the AMBITION trial. Chest. 2023, 164:1518-30. 10.1016\/j.chest.2023.06.023","journal-title":"Chest"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon O","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, et al.. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015, 373:2522-33. 10.1056\/NEJMoa1503184","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.12.013","article-title":"Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study","volume":"39","author":"Sitbon O","year":"2020","unstructured":"Sitbon O, Chin KM, Channick RN, et al.. Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study. J Heart Lung Transplant. 2020, 39:300-9. 10.1016\/j.healun.2019.12.013","journal-title":"J Heart Lung Transplant"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2024.08.019","article-title":"Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: a post-hoc analysis of the GRIPHON study","volume":"43","author":"Benza RL","year":"2024","unstructured":"Benza RL, Chin KM, Gaine S, et al.. Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: a post-hoc analysis of the GRIPHON study. J Heart Lung Transplant. 2024, 43:1998-2007. 10.1016\/j.healun.2024.08.019","journal-title":"J Heart Lung Transplant"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension","volume":"78","author":"Chin KM","year":"2021","unstructured":"Chin KM, Sitbon O, Doelberg M, et al.. Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol. 2021, 78:1393-403. 10.1016\/j.jacc.2021.07.057","journal-title":"J Am Coll Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3319","article-title":"Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities","volume":"26","author":"McLaughlin VV","year":"2024","unstructured":"McLaughlin VV, Sitbon O, Chin KM, et al.. Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities. Eur J Heart Fail. 2024, 26:2379-91. 10.1002\/ejhf.3319","journal-title":"Eur J Heart Fail"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01107-2023","article-title":"Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial","volume":"62","author":"Souza R","year":"2023","unstructured":"Souza R, Badesch DB, Ghofrani HA, et al.. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial. Eur Respir J. 2023, 62:10.1183\/13993003.01107-2023","journal-title":"Eur Respir J"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01435-2024","article-title":"A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA","volume":"66","author":"Preston IR","year":"2025","unstructured":"Preston IR, Badesch D, Ghofrani HA, et al.. A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. Eur Respir J. 2025, 66:10.1183\/13993003.01435-2024","journal-title":"Eur Respir J"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217741480","article-title":"Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study","volume":"8","author":"Benza RL","year":"2018","unstructured":"Benza RL, Raina A, Gupta H, et al.. Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study. Pulm Circ. 2018, 8:2045893217741480. 10.1177\/2045893217741480","journal-title":"Pulm Circ"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02425-2016","article-title":"RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors","volume":"50","author":"Hoeper MM","year":"2017","unstructured":"Hoeper MM, Simonneau G, Corris PA, et al.. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017, 50:10.1183\/13993003.02425-2016","journal-title":"Eur Respir J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.10.013","article-title":"Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study","volume":"41","author":"Benza RL","year":"2022","unstructured":"Benza RL, Boucly A, Farber HW, et al.. Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study. J Heart Lung Transplant. 2022, 41:411-20. 10.1016\/j.healun.2021.10.013","journal-title":"J Heart Lung Transplant"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107910","article-title":"Riociguat in pulmonary arterial hypertension: application of the 4-strata COMPERA 2.0 risk assessment tool in the PATENT studies","volume":"236","author":"Hoeper MM","year":"2025","unstructured":"Hoeper MM, Rosenkranz S, Badesch DB, et al.. Riociguat in pulmonary arterial hypertension: application of the 4-strata COMPERA 2.0 risk assessment tool in the PATENT studies. Respir Med. 2025, 236:107910. 10.1016\/j.rmed.2024.107910","journal-title":"Respir Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020973124","article-title":"Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study","volume":"10","author":"Simonneau G","year":"2020","unstructured":"Simonneau G, Ghofrani HA, Corris PA, et al.. Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. Pulm Circ. 2020, 10:2045894020973124. 10.1177\/2045894020973124","journal-title":"Pulm Circ"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2024.08.018","article-title":"Riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: data from interventional trials","volume":"44","author":"Rosenkranz S","year":"2025","unstructured":"Rosenkranz S, Ghofrani HA, Hoeper MM, et al.. Riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: data from interventional trials. J Heart Lung Transplant. 2025, 44:135-46. 10.1016\/j.healun.2024.08.018","journal-title":"J Heart Lung Transplant"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2022.08.006","article-title":"Contemporary risk scores predict clinical worsening in pulmonary arterial hypertension: an analysis of FREEDOM-EV","volume":"41","author":"Benza RL","year":"2022","unstructured":"Benza RL, Gomberg-Maitland M, Farber HW, et al.. Contemporary risk scores predict clinical worsening in pulmonary arterial hypertension: an analysis of FREEDOM-EV. J Heart Lung Transplant. 2022, 41:1572-80. 10.1016\/j.healun.2022.08.006","journal-title":"J Heart Lung Transplant"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-026-03497-4","article-title":"Efficacy and safety of oral treprostinil in patients with pulmonary arterial hypertension on background monotherapy or dual therapy","volume":"43","author":"Lachant D","year":"2026","unstructured":"Lachant D, Raina A, Krishnan M, et al.. Efficacy and safety of oral treprostinil in patients with pulmonary arterial hypertension on background monotherapy or dual therapy. Adv Ther. 2026, 43:1308-26. 10.1007\/s12325-026-03497-4","journal-title":"Adv Ther"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020977025","article-title":"Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies","volume":"10","author":"Tonelli AR","year":"2020","unstructured":"Tonelli AR, Sahay S, Gordon KW, Edwards LD, Allmon AG, Broderick M, Nelsen AC. Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies. Pulm Circ. 2020, 10:2045894020977025. 10.1177\/2045894020977025","journal-title":"Pulm Circ"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107374","article-title":"Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil in pulmonary arterial hypertension","volume":"218","author":"Miller CE","year":"2023","unstructured":"Miller CE, Franco V, Smith JS, et al.. Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil in pulmonary arterial hypertension. Respir Med. 2023, 218:107374. 10.1016\/j.rmed.2023.107374","journal-title":"Respir Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1142721","article-title":"Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials","volume":"10","author":"Wang A","year":"2023","unstructured":"Wang A, Chen M, Zhuang Q, et al.. Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials. Front Cardiovasc Med. 2023, 10:1142721. 10.3389\/fcvm.2023.1142721","journal-title":"Front Cardiovasc Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202009-3698OC","article-title":"Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension","volume":"204","author":"Boucly A","year":"2021","unstructured":"Boucly A, Savale L, Ja\u00efs X, et al.. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021, 204:842-54. 10.1164\/rccm.202009-3698OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202004-1006OC","article-title":"Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension","volume":"203","author":"Badagliacca R","year":"2021","unstructured":"Badagliacca R, D'Alto M, Ghio S, et al.. Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021, 203:484-92. 10.1164\/rccm.202004-1006OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00298-2022","article-title":"Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension","volume":"8","author":"Badagliacca R","year":"2022","unstructured":"Badagliacca R, D'Alto M, Ghio S, et al.. Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension. ERJ Open Res. 2022, 8:10.1183\/23120541.00298-2022","journal-title":"ERJ Open Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.08.016","article-title":"Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension","volume":"39","author":"D'Alto M","year":"2020","unstructured":"D'Alto M, Badagliacca R, Lo Giudice F, et al.. Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension. J Heart Lung Transplant. 2020, 39:1389-97. 10.1016\/j.healun.2020.08.016","journal-title":"J Heart Lung Transplant"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2017.08.009","article-title":"Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension","volume":"37","author":"Badagliacca R","year":"2018","unstructured":"Badagliacca R, D'Alto M, Ghio S, et al.. Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. J Heart Lung Transplant. 2018, 37:365-75. 10.1016\/j.healun.2017.08.009","journal-title":"J Heart Lung Transplant"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2022.10.003","article-title":"Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: a COMPERA analysis","volume":"42","author":"Rosenkranz S","year":"2023","unstructured":"Rosenkranz S, Pausch C, Coghlan JG, et al.. Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: a COMPERA analysis. J Heart Lung Transplant. 2023, 42:102-14. 10.1016\/j.healun.2022.10.003","journal-title":"J Heart Lung Transplant"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13162","article-title":"Longitudinal changes in risk status in pulmonary arterial hypertension","volume":"8","author":"Bouzina H","year":"2021","unstructured":"Bouzina H, R\u00e5degran G, Butler O, et al.. Longitudinal changes in risk status in pulmonary arterial hypertension. ESC Heart Fail. 2021, 8:680-90. 10.1002\/ehf2.13162","journal-title":"ESC Heart Fail"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12440","article-title":"Treatment pathways in Finnish patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH)","volume":"15","author":"Pentik\u00e4inen M","year":"2025","unstructured":"Pentik\u00e4inen M, Simonen P, Leskel\u00e4 P, et al.. Treatment pathways in Finnish patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). Pulm Circ. 2025, 15:e12440. 10.1002\/pul2.12440","journal-title":"Pulm Circ"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2026.1745171","article-title":"Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension","volume":"13","author":"Cui X","year":"2026","unstructured":"Cui X, Hu X, Qin X, Li H, Xu X, Liu H, Ji Q. Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension. Front Cardiovasc Med. 2026, 13:1745171. 10.3389\/fcvm.2026.1745171","journal-title":"Front Cardiovasc Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12351","article-title":"Evaluating the efficacy and safety of oral triple sequential combination therapy for treating patients with pulmonary arterial hypertension: a multicenter retrospective study","volume":"14","author":"Zhao QH","year":"2024","unstructured":"Zhao QH, Chen J, Chen FD, et al.. Evaluating the efficacy and safety of oral triple sequential combination therapy for treating patients with pulmonary arterial hypertension: a multicenter retrospective study. Pulm Circ. 2024, 14:e12351. 10.1002\/pul2.12351","journal-title":"Pulm Circ"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.14744\/AnatolJCardiol.2025.5976","article-title":"Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Center Study?","volume":"30","author":"Tokg\u00f6z HC","year":"2026","unstructured":"Tokg\u00f6z HC, Kaymaz C, K\u00fclt\u00fcrsay B, et al.. Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Center Study?. Anatol J Cardiol. 2026, 30:248-58. 10.14744\/AnatolJCardiol.2025.5976","journal-title":"Anatol J Cardiol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1177\/17534666231199693","article-title":"Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: real world experience","volume":"17","author":"Deshwal H","year":"2023","unstructured":"Deshwal H, Weinstein T, Salyer R, et al.. Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: real world experience. Ther Adv Respir Dis. 2023, 17:10.1177\/17534666231199693","journal-title":"Ther Adv Respir Dis"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.04.010","article-title":"Effectiveness of a prostacyclin IP receptor agonist in patients with pulmonary arterial hypertension in the real-world Andalusian setting: the RAMPHA study","volume":"46","author":"Bravo-Marqu\u00e9s R","year":"2024","unstructured":"Bravo-Marqu\u00e9s R, Becerra-Mu\u00f1oz V, Esp\u00edldora-Hern\u00e1ndez F, et al.. Effectiveness of a prostacyclin IP receptor agonist in patients with pulmonary arterial hypertension in the real-world Andalusian setting: the RAMPHA study. Clin Ther. 2024, 46:509-14. 10.1016\/j.clinthera.2024.04.010","journal-title":"Clin Ther"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2026.107585","article-title":"Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and\/or selexipag as part of a combination treatment (INSPECTIO)","volume":"162","author":"D'Alto M","year":"2026","unstructured":"D'Alto M, Scelsi L, Giuliani L, et al.. Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and\/or selexipag as part of a combination treatment (INSPECTIO). Vascul Pharmacol. 2026, 162:107585. 10.1016\/j.vph.2026.107585","journal-title":"Vascul Pharmacol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01197-5","article-title":"Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study","volume":"20","author":"Escribano-Subias P","year":"2020","unstructured":"Escribano-Subias P, L\u00f3pez R, Almenar L, et al.. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study. BMC Pulm Med. 2020, 20:154. 10.1186\/s12890-020-01197-5","journal-title":"BMC Pulm Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-03388-w","article-title":"Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey","volume":"24","author":"Vaidya A","year":"2024","unstructured":"Vaidya A, Sketch MR, Broderick M, Shlobin OA. Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey. BMC Pulm Med. 2024, 24:574. 10.1186\/s12890-024-03388-w","journal-title":"BMC Pulm Med"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.70226","article-title":"Real-world performance of sotatercept in pulmonary arterial hypertension patients with cardiopulmonary comorbidities","volume":"15","author":"Gomez Rojas O","year":"2025","unstructured":"Gomez Rojas O, Mitchell S, Peterson JA, Kalra S, Bryant A, Ataya A. Real-world performance of sotatercept in pulmonary arterial hypertension patients with cardiopulmonary comorbidities. Pulm Circ. 2025, 15:e70226. 10.1002\/pul2.70226","journal-title":"Pulm Circ"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12285","article-title":"Peak steps: Capacity for activity improves after adding approved therapy in pulmonary arterial hypertension","volume":"13","author":"Lachant D","year":"2023","unstructured":"Lachant D, Light A, Lachant M, Annis J, Hemnes A, Brittain E, White RJ. Peak steps: Capacity for activity improves after adding approved therapy in pulmonary arterial hypertension. Pulm Circ. 2023, 13:e12285. 10.1002\/pul2.12285","journal-title":"Pulm Circ"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1177\/2040622318779749","article-title":"Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension","volume":"9","author":"Enderby CY","year":"2018","unstructured":"Enderby CY, Burger C. Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension. Ther Adv Chronic Dis. 2018, 9:171-7. 10.1177\/2040622318779749","journal-title":"Ther Adv Chronic Dis"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00155-8","article-title":"Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials","volume":"11","author":"Blette BS","year":"2023","unstructured":"Blette BS, Moutchia J, Al-Naamani N, et al.. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials. Lancet Respir Med. 2023, 11:873-82. 10.1016\/S2213-2600(23)00155-8","journal-title":"Lancet Respir Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/534907-treatment-strategies-for-achieving-and-maintaining-low-risk-status-in-pulmonary-arterial-hypertension-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:00:58Z","timestamp":1792357258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/534907-treatment-strategies-for-achieving-and-maintaining-low-risk-status-in-pulmonary-arterial-hypertension-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":63,"URL":"https:\/\/doi.org\/10.7759\/cureus.118129","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,18]]}}}